North America to be Largest Catalog Peptides Market in Future

Every year, over 9.5 million people die of cancer each year, according to the World Health Organization (WHO). This is because either patients are diagnosed in later stages, or the drugs aren’t able to target tumors that well. A lot of cancers are formed due to the disruption in the pathways activated by peptides, which are essentially short chains of amino acids; a peptide of more than 50 amino acids is known as a protein. Since the establishment of the fact that protein pathway disruption is a potential cause of cancer, extensive research and development (R&D) has been put in to remedy this.

Thus, with the rising prevalence of cancer and fruitful R&D, the catalog peptides market is predicted to grow from $238.4 million in 2018 to $332.1 million by 2024, at a 5.8% CAGR during 2019–2024 (forecast period). The term catalog peptide refers to the artificially synthesized peptide drugs which are readily available with biotechnology and pharmaceutical companies, as opposed to those that are customized as per user preference and the specific application.

There are numerous types of peptides that are being studied or available, inclum mding calcitonin gene-related, cyclic, amyloid, caspase-related, amylin, adrenomedullin, cosmetic, tau, G-protein-coupled receptors (GPCR), and antimicrobial. Among these, cyclic peptides are consumed in the highest amounts, as they possess anti-tumor, antibacterial, and immunosuppressive properties. In addition, such peptides are stable and highly selective toward the targeted molecules. Thus, with their wide-ranging application and rising incidence of cancer, such biomolecules will continue witnessing a high demand, especially as R&D results in more kinds of improved cyclic peptides.

Presently, North America makes the largest contribution to the catalog peptides market, owing to the presence of a number of biopharmaceutical companies, increasing R&D investments for widening the application area of such products, and adoption of improved technologies for manufacturing. Within the region, the U.S. consumes such drugs in higher amounts, owing to its increasing incidence of chronic diseases, especially cancer. Moreover, numerous drugs are receiving approvals from the Food and Drug Administration, which is leading to their rising availability for the treatment of various diseases.

Hence, with the rising R&D activities and prevalence of cancer, the demand for catalog peptides will also grow.

This study covers

• Historical and the present size of the catalog peptides market
• Major factors driving the market and their impact during the short, medium, and long terms
• Market restraints and their impact during the short, medium, and long terms
• Recent trends and evolving opportunities for the market participants
• Historical and the present size of the market segments and understand their comparative future potential

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact: P&S Intelligence Toll-free: +1-888-778-7886 (USA/Canada) International: +1-347-960-6455 Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com